Can GLP-1 Medications Like Ozempic Help With Alcohol Use Disorder?

What Are GLP-1 Medications?

GLP-1 receptor agonists — including semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda, Victoza) — were originally developed to treat type 2 diabetes and obesity. They mimic glucagon-like peptide-1, a hormone that regulates blood sugar, digestion, and appetite.

But GLP-1 receptors aren't only found in the gut and pancreas. They're also expressed in key regions of the brain's reward system — the same circuits that drive cravings for alcohol, food, and other substances. That's where things get interesting for addiction medicine.

What Does the Research Actually Show?

The 2025 JAMA Psychiatry Randomized Clinical Trial

The most rigorous human evidence to date comes from a phase 2, double-blind, randomized controlled trial published in JAMA Psychiatry in April 2025 (Hendershot et al.). Researchers enrolled 48 adults with alcohol use disorder and randomly assigned them to receive low-dose weekly semaglutide or placebo for 9 weeks.

The results were striking. Compared to placebo, semaglutide:

• Significantly reduced weekly alcohol cravings with medium-to-large effect sizes
• Reduced the amount of alcohol consumed in a laboratory self-administration test
• Produced reductions in several measures of weekly drinking
• Reduced cigarette use in participants who smoked — suggesting broad effects on addictive reward

The researchers noted that the magnitude of semaglutide's effects appeared "potentially greater than is often seen in similar studies with existing AUD medications" — even at the lowest clinical doses tested.

Phase 3 Trial: 41% Reduction in Heavy Drinking Days

A subsequent Phase 3 trial enrolled 108 treatment-seeking patients with AUD and comorbid obesity. Participants received either semaglutide or placebo weekly for 26 weeks alongside standard cognitive behavioral therapy.

Those receiving semaglutide experienced a 41.1% reduction in heavy drinking days — a 13.7 percentage point greater reduction than the placebo group. The NIH highlighted this trial as evidence that GLP-1 therapy meaningfully augments existing AUD treatment.

Real-World Population Data

A 2024 study published in Nature Communications analyzed real-world health records and found that individuals using semaglutide were at markedly lower risk of both new-onset alcohol use disorder and AUD recurrence — with a median follow-up of more than 8 years.

Lancet Systematic Review

A systematic review published in eClinicalMedicine (The Lancet) confirmed that across multiple studies, GLP-1 receptor agonist use was consistently associated with reductions in alcohol consumption — in patients with obesity, type 2 diabetes, and AUD.

How Do GLP-1s Actually Reduce Alcohol Cravings?

The mechanism comes down to neuroscience. GLP-1 receptors are densely expressed in three key brain regions:

• Ventral tegmental area (VTA) — the brain's primary dopamine production hub
• Nucleus accumbens — the "reward center" that drives craving and motivation to drink
• Prefrontal cortex — involved in impulse control and decision-making

When semaglutide activates GLP-1 receptors in these areas, it blunts dopamine release in response to alcohol. The drink still happens — but the brain's reward signal is dampened. Over time, this reduces the drive to drink.

This is also why GLP-1 users often report losing interest not just in food and alcohol, but in gambling, shopping, and other compulsive behaviors — the mechanism acts broadly on the reward system.

Who Is This Treatment For?

The short answer: both ends of the spectrum — and everyone in between.

If you're sober-curious — you drink socially, it's starting to feel like too much, and you want to pull back before it becomes a bigger problem — GLP-1 therapy can quiet the background noise around alcohol without requiring you to label yourself or commit to abstinence. Many patients simply find drinking loses its appeal over time.

If alcohol is destroying your life — your relationships, your job, your health, and you've tried to stop more times than you can count — this is also for you. Especially you. The combined GLP-1 and naltrexone approach was developed with severe AUD in mind. When cravings feel like a physical force you can't fight, changing the brain chemistry behind those cravings isn't giving up — it's the most direct solution available.

• Sober-curious individuals who want to drink less without quitting entirely
• Moderate-to-heavy drinkers who have tried willpower, therapy, or AA without lasting success
• People with severe AUD for whom alcohol has become a daily necessity
• Anyone who wants a private, judgment-free approach from home
• Patients with comorbid obesity or metabolic concerns alongside drinking

One important note: GLP-1 therapy is not appropriate for initial alcohol detoxification. If you are physically dependent on alcohol and concerned about withdrawal symptoms, please seek medical supervision before stopping. We can help you figure out the right next step.

GLP-1s vs. Naltrexone: Do You Need Both?

Naltrexone — particularly via the Sinclair Method — has decades of clinical evidence behind it and remains a first-line FDA-approved treatment for AUD. It's also relatively inexpensive, making it accessible even for patients with limited coverage. For many people, naltrexone alone produces meaningful, lasting change.

But for patients who need more — whether because cravings are intense, prior treatments haven't worked, or the pull toward alcohol feels deeper than willpower alone can address — combining naltrexone with a GLP-1 medication may be significantly more effective. The two work through entirely different mechanisms: naltrexone blocks the opioid reward response to alcohol, while GLP-1s dampen the broader dopamine drive behind craving. Together, they address the problem from two directions at once.

This combined approach is supported by our medical team's clinical guidance — and it's personal for our founder. Project Recovery was built in part from his own experience with this combination. In his words: "It saved my life." That's not marketing. It's why this practice exists.

Our providers assess your specific situation and goals to recommend the right protocol — naltrexone alone, GLP-1 monotherapy, or the combined approach — and work with your insurance to make it as affordable as possible.

How Project Recovery Can Help

Project Recovery is one of the only telemedicine providers in the US currently prescribing GLP-1 medications specifically for alcohol use disorder. Our medical director is licensed in 16 states. Most insurance is accepted — many patients pay little or nothing out of pocket.

You don't need to have already stopped drinking to start. You don't need a referral. You can verify your insurance in under a minute and speak with a provider from home.

Sources & Further Reading

1. Hendershot CS et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025.
2. NIH News Release. Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking. National Institutes of Health.
3. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nature Communications. 2024.
4. Association between GLP-1 receptor agonists use and change in alcohol consumption: a systematic review. eClinicalMedicine (The Lancet). 2024.
5. NIAAA. Semaglutide Shows Promise as a Potential Alcohol Use Disorder Medication. National Institute on Alcohol Abuse and Alcoholism.
6. The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. PMC / British Journal of Pharmacology. 2022.